Combined familial hyperlipidemia with dysfunctional VLDL clearance is a group of disorder in which mutations cause an impaired elimination of VLDL from plasma.
1. |
DeMattos RB et al. (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. |
2. |
Dodart JC et al. (2005) Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. |
3. |
Schächter F et al. (1994) Genetic associations with human longevity at the APOE and ACE loci. |
4. |
Kadotani H et al. (2001) Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. |
5. |
Spirin V et al. (2007) Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. |
6. |
Kathiresan S et al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. |
7. |
Aulchenko YS et al. (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. |
8. |
Sparkes RS et al. (1987) Human genes involved in lipolysis of plasma lipoproteins: mapping of loci for lipoprotein lipase to 8p22 and hepatic lipase to 15q21. |
10. |
Greenberg SM et al. (1995) Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. |
11. |
Nicoll JA et al. (1996) High frequency of apolipoprotein E epsilon 2 in patients with cerebral hemorrhage due to cerebral amyloid angiopathy. |
12. |
Yamada M et al. (1996) Lack of an association between apolipoprotein E epsilon 4 and cerebral amyloid angiopathy in elderly Japanese. |
13. |
Nicoll JA et al. (1997) High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. |
14. |
Greenberg SM et al. (1998) Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. |
15. |
O'Donnell HC et al. (2000) Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. |
16. |
Evans D et al. (2005) Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. |
17. |
Benlian P et al. (1996) Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. |
18. |
Burt TD et al. (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. |
21. |
Emi M et al. (1990) Missense mutation (Gly----Glu188) of human lipoprotein lipase imparting functional deficiency. |
22. |
Chen Y et al. (2008) Variations in DNA elucidate molecular networks that cause disease. |
23. |
Feussner G et al. (1996) Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia. |
24. |
Henderson HE et al. (1992) The lipoprotein lipase Gly188----Glu mutation in South Africans of Indian descent: evidence suggesting common origins and an increased frequency. |
25. |
Hata A et al. (1992) Missense mutations in exon 5 of the human lipoprotein lipase gene. Inactivation correlates with loss of dimerization. |
26. |
Normand T et al. (1992) Geographic distribution and genealogy of mutation 207 of the lipoprotein lipase gene in the French Canadian population of Québec. |
27. |
Sprecher DL et al. (1992) Trp64----nonsense mutation in the lipoprotein lipase gene. |
28. |
Chimienti G et al. (1992) A G----C change at the donor splice site of intron 1 causes lipoprotein lipase deficiency in a southern-Italian family. |
29. |
Gotoda T et al. (1992) A newly identified null allelic mutation in the human lipoprotein lipase (LPL) gene of a compound heterozygote with familial LPL deficiency. |
30. |
Bergeron J et al. (1992) Prevalence, geographical distribution and genealogical investigations of mutation 188 of lipoprotein lipase gene in the French Canadian population of Québec. |
31. |
Ishimura-Oka K et al. (1992) A missense mutation (Trp86----Arg) in exon 3 of the lipoprotein lipase gene: a cause of familial chylomicronemia. |
32. |
Ma Y et al. (1992) A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. |
33. |
Heizmann C et al. (1991) DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels. |
34. |
Dichek HL et al. (1991) Identification of two separate allelic mutations in the lipoprotein lipase gene of a patient with the familial hyperchylomicronemia syndrome. |
37. |
Gotoda T et al. (1991) Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. |
38. |
Paulweber B et al. (1991) Molecular basis of lipoprotein lipase deficiency in two Austrian families with type I hyperlipoproteinemia. |
40. |
De Braekeleer M et al. (1991) Founder effect in familial hyperchylomicronemia among French Canadians of Quebec. |
41. |
Monsalve MV et al. (1990) A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries. |
42. |
Ameis D et al. (1991) Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene. |
43. |
Ma Y et al. (1991) A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians. |
44. |
Beg OU et al. (1990) Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176----Thr) leads to abnormal heparin binding and loss of enzymic activity. |
45. |
Hata A et al. (1990) Compound heterozygote for lipoprotein lipase deficiency: Ser--Thr244 and transition in 3' splice site of intron 2 (AG--AA) in the lipoprotein lipase gene. |
46. |
Devlin RH et al. (1990) Partial gene duplication involving exon-Alu interchange results in lipoprotein lipase deficiency. |
47. |
Emi M et al. (1990) Lipoprotein lipase deficiency resulting from a nonsense mutation in exon 3 of the lipoprotein lipase gene. |
48. |
Wilson DE et al. (1990) Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. |
49. |
Langlois S et al. (1989) A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. |
50. |
Kirchgessner TG et al. (1989) Organization of the human lipoprotein lipase gene and evolution of the lipase gene family. |
51. |
Deeb SS et al. (1989) Structure of the human lipoprotein lipase gene. |
52. |
Heinzmann C et al. (1987) RFLP for the human lipoprotein lipase (LPL) gene: HindIII. |
53. |
Funke H et al. (1987) Hind III RFLP in the lipoprotein lipase gene, (LPL). |
54. |
Li SR et al. (1988) Pvu-II RFLP at the human lipoprotein lipase (LPL) gene locus. |
55. |
Funke H et al. (1988) Bst NI (Eco RII) RFLP in the lipoprotein lipase gene (LPL). |
56. |
Kirchgessner TG et al. (1987) The sequence of cDNA encoding lipoprotein lipase. A member of a lipase gene family. |
57. |
Wion KL et al. (1987) Human lipoprotein lipase complementary DNA sequence. |
58. |
Wilson DE et al. (1983) Phenotypic heterogeneity in the extended pedigree of a proband with lipoprotein lipase deficiency. |
59. |
Levak-Frank S et al. (1995) Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. |
60. |
Yang WS et al. (1995) A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. |
61. |
Lo JY et al. (1995) Lipoprotein lipase: role of intramolecular disulfide bonds in enzyme catalysis. |
62. |
Ma Y et al. (1994) Recurrent missense mutations at the first and second base of codon Arg243 in human lipoprotein lipase in patients of different ancestries. |
63. |
Emi M et al. (1993) Structure, organization, and chromosomal mapping of the human macrophage scavenger receptor gene. |
64. |
Kobayashi J et al. (1993) A missense mutation (Ala334-->Thr) in exon 7 of the lipoprotein lipase gene in a case with type I hyperlipidemia. |
65. |
Wood S et al. (1993) Support for founder effect for two lipoprotein lipase (LPL) gene mutations in French Canadians by analysis of GT microsatellites flanking the LPL gene. |
66. |
Pepe G et al. (1994) A new Italian case of lipoprotein lipase deficiency: a Leu365- > Val change resulting in loss of enzyme activity. |
68. |
Wilson DE et al. (1993) Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes. |
69. |
Miesenböck G et al. (1993) Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. |
70. |
Mattei MG et al. (1993) Assignment of the human lipoprotein lipase (LPL) gene to chromosome band 8p22. |
71. |
Ma Y et al. (1993) Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene. |
72. |
Reymer PW et al. (1995) A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. |
73. |
Buscà R et al. (1996) The mutation Gly142-->Glu in human lipoprotein lipase produces a missorted protein that is diverted to lysosomes. |
74. |
Ginzinger DG et al. (1996) A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats. |
76. |
Benlian P et al. (1996) Complete paternal isodisomy for chromosome 8 unmasked by lipoprotein lipase deficiency. |
77. |
Henderson HE et al. (1996) A new mutation destroying disulphide bridging in the C-terminal domain of lipoprotein lipase. |
78. |
de Bruin TW et al. (1996) Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. |
79. |
Wittrup HH et al. (1997) A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. |
80. |
Mailly F et al. (1997) Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. |
81. |
Fisher RM et al. (1997) Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. |
82. |
Kastelein JJ et al. (1998) The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. |
83. |
Nickerson DA et al. (1998) DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. |
84. |
Clark AG et al. (1998) Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. |
85. |
Henderson HE et al. (1998) Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event. |
86. |
Wittrup HH et al. (1999) Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study. |
87. |
Boer JM et al. (1999) Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins. |
88. |
Bertolini S et al. (2000) Pseudodominance of lipoprotein lipase (LPL) deficiency due to a nonsense mutation (Tyr302>Term) in exon 6 of LPL gene in an Italian family from Sardinia (LPL(Olbia)). |
89. |
Hoffmann MM et al. (2000) Type I hyperlipoproteinemia due to a novel loss of function mutation of lipoprotein lipase, Cys(239)-->Trp, associated with recurrent severe pancreatitis. |
92. |
Clee SM et al. (2001) The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. |
93. |
Yagyu H et al. (2003) Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. |
94. |
Ling C et al. (2003) Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. |
95. |
Yang W et al. (2004) Lipoprotein lipase gene is in linkage with blood pressure phenotypes in Chinese pedigrees. |
96. |
López-Miranda J et al. (2004) The influence of lipoprotein lipase gene variation on postprandial lipoprotein metabolism. |
97. |
Pruneta-Deloche V et al. (2005) Combination of circulating antilipoprotein lipase (Anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia. |
98. |
Goodarzi MO et al. (2005) The 3' untranslated region of the lipoprotein lipase gene: haplotype structure and association with post-heparin plasma lipase activity. |
100. |
Zhao T et al. (2006) Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia. |
101. |
Frikke-Schmidt R et al. (2007) Subsets of SNPs define rare genotype classes that predict ischemic heart disease. |
102. |
Goodarzi MO et al. (2007) Haplotypes in the lipoprotein lipase gene influence fasting insulin and discovery of a new risk haplotype. |
103. |
Kim MS et al. (2008) Protein kinase D is a key regulator of cardiomyocyte lipoprotein lipase secretion after diabetes. |
104. |
Kim YJ et al. (2011) Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. |
105. |
Davies BS et al. (2012) Assessing mechanisms of GPIHBP1 and lipoprotein lipase movement across endothelial cells. |
106. |
Richardson K et al. (2013) Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site. |
107. |
Utermann G et al. (1980) Genetics of the apolipoprotein E system in man. |
108. |
Gregg RE et al. (1981) Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. |
109. |
Hazzard WR et al. (1981) Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia. |
110. |
Zannis VI et al. (1981) Human apolipoprotein E isoprotein subclasses are genetically determined. |
111. |
St Clair D et al. (1995) Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. |
112. |
Bennett C et al. (1995) Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. |
113. |
Masliah E et al. (1995) Neurodegeneration in the central nervous system of apoE-deficient mice. |
114. |
Farrer LA et al. (1995) Allele epsilon 4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. |
115. |
Polvikoski T et al. (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. |
116. |
Levy-Lahad E et al. (1995) Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. |
117. |
van Ree JH et al. (1995) Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. |
118. |
Nicoll JA et al. (1995) Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. |
119. |
Matsunaga A et al. (1995) Population frequency of apolipoprotein E5 (Glu3>Lys) and E7 (Glu244>Lys, Glu245-->Lys) variants in western Japan. |
120. |
Mann WA et al. (1995) Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). |
121. |
Boisvert WA et al. (1995) Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. |
122. |
van Gool WA et al. (1995) A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Ageing. |
123. |
Kashyap VS et al. (1995) Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. |
124. |
Mui S et al. (1995) Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. |
125. |
Osuntokun BO et al. (1995) Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. |
126. |
Kamboh MI et al. (1995) APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. |
127. |
Tabaton M et al. (1995) Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy. |
128. |
Blennow K et al. (1994) Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. |
129. |
Royston MC et al. (1994) Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. |
131. |
Strittmatter WJ et al. (1995) Apolipoprotein E and Alzheimer disease. |
132. |
Lippa CF et al. (1995) Apolipoprotein E genotype and Lewy body disease. |
133. |
de Knijff P et al. (1994) Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. |
134. |
Bétard C et al. (1994) Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia. |
135. |
Linton MF et al. (1995) Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. |
136. |
Talbot C et al. (1994) Protection against Alzheimer's disease with apoE epsilon 2. |
137. |
Corder EH et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. |
138. |
Yoshizawa T et al. (1994) Dose-dependent association of apolipoprotein E allele epsilon 4 with late-onset, sporadic Alzheimer's disease. |
139. |
Lucotte G et al. (1994) Apolipoprotein E-epsilon 4 allele doses in late-onset Alzheimer's disease. |
140. |
Kawamata J et al. (1994) Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. |
142. |
Nalbantoglu J et al. (1994) Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. |
143. |
Marder K et al. (1994) The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. |
144. |
Sanan DA et al. (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. |
145. |
Frisoni GB et al. (1994) Apolipoprotein E epsilon 4 allele frequency in vascular dementia and Alzheimer's disease. |
146. |
Borgaonkar DS et al. (1993) Linkage of late-onset Alzheimer's disease with apolipoprotein E type 4 on chromosome 19. |
147. |
None (1993) Apolipoprotein E and Alzheimer's disease. |
148. |
Poirier J et al. (1993) Apolipoprotein E polymorphism and Alzheimer's disease. |
149. |
Saunders AM et al. (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. |
150. |
Corder EH et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. |
151. |
Saunders AM et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. |
152. |
Strittmatter WJ et al. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. |
153. |
Strittmatter WJ et al. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. |
154. |
van den Maagdenberg AM et al. (1993) Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. |
155. |
Garlepp MJ et al. (1995) Apolipoprotein E epsilon 4 in inclusion body myositis. |
156. |
Lannfelt L et al. (1995) Apolipoprotein epsilon 4 allele in Swedish twins and siblings with Alzheimer disease. |
157. |
Reiman EM et al. (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. |
158. |
None (1996) Mouse models of atherosclerosis. |
159. |
Tomimoto H et al. (1995) Immunohistochemical study of apolipoprotein E in human cerebrovascular white matter lesions. |
160. |
Myers RH et al. (1996) Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. |
161. |
Poirier J et al. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. |
162. |
Blesa R et al. (1996) High apolipoprotein E epsilon 4 allele frequency in age-related memory decline. |
163. |
Tang MX et al. (1996) Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. |
164. |
Payami H et al. (1996) Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. |
165. |
Hyman BT et al. (1996) Apolipoprotein E epsilon4/4 in a neuropathologically normal very elderly individual. |
166. |
Egensperger R et al. (1996) The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. |
167. |
Slooter AJ et al. (1996) APOE genotyping in differential diagnosis of Alzheimer's disease. |
168. |
Olichney JM et al. (1996) The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. |
169. |
Kurz A et al. (1996) Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. |
170. |
Growdon JH et al. (1996) Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. |
171. |
Asada T et al. (1996) ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease. |
172. |
Harrington CR et al. (1995) Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. |
173. |
Gerdes LU et al. (1996) The apolipoprotein E polymorphism in Greenland Inuit in its global perspective. |
174. |
Bickeböller H et al. (1997) Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. |
175. |
Payami H et al. (1997) A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. |
176. |
Oikawa S et al. (1997) Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy. |
177. |
Sullivan PM et al. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. |
178. |
Houlden H et al. (1998) ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. |
179. |
Sullivan PM et al. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. |
180. |
Meyer MR et al. (1998) APOE genotype predicts whennot whetherone is predisposed to develop Alzheimer disease. |
181. |
Friedman G et al. (1999) Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. |
182. |
Kehoe P et al. (1999) Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. |
183. |
Holtzman DM et al. (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. |
184. |
Wiebusch H et al. (1999) Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. |
185. |
Teasdale GM et al. (1997) Association of apolipoprotein E polymorphism with outcome after head injury. |
186. |
Matsunaga A et al. (1999) A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. |
187. |
McCarron MO et al. (1999) APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. |
188. |
Lambert JC et al. (2000) Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. |
189. |
Holtzman DM et al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. |
190. |
Corbo RM et al. (1999) Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? |
191. |
Raber J et al. (2000) Apolipoprotein E and cognitive performance. |
192. |
Wiggs JL et al. (2000) Genome-wide scan for adult onset primary open angle glaucoma. |
193. |
Yaffe K et al. (2000) Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. |
194. |
Mitchell C et al. (2000) Therapeutic liver repopulation in a mouse model of hypercholesterolemia. |
195. |
Wang HY et al. (2000) Apolipoprotein E is a genetic risk factor for fetal iodine deficiency disorder in China. |
196. |
Ishigaki Y et al. (2000) Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. |
197. |
Fullerton SM et al. (2000) Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. |
199. |
Tangirala RK et al. (2001) Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. |
200. |
Salero E et al. (2001) Transcription factors Zic1 and Zic2 bind and transactivate the apolipoprotein E gene promoter. |
202. |
Reynolds WF et al. (2000) MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. |
203. |
Nguyen TT et al. (2000) Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]. |
204. |
Wang JC et al. (2000) Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. |
205. |
Frikke-Schmidt R et al. (2001) APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease. |
206. |
Chapman J et al. (2001) APOE genotype is a major predictor of long-term progression of disability in MS. |
207. |
Bonay P et al. (2001) Apolipoprotein E4 stimulates sulfation of glycosaminoglycans in neural cells. |
208. |
Peskind ER et al. (2001) Increased CSF cortisol in AD is a function of APOE genotype. |
209. |
Anderson DH et al. (2001) Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. |
210. |
Broderick J et al. (2001) Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. |
211. |
Ghebremedhin E et al. (2001) Gender and age modify the association between APOE and AD-related neuropathology. |
212. |
Zubenko GS et al. (2001) D10S1423 identifies a susceptibility locus for Alzheimer's disease in a prospective, longitudinal, double-blind study of asymptomatic individuals. |
213. |
Mortensen EL et al. (2001) A gender difference in the association between APOE genotype and age-related cognitive decline. |
214. |
Huang Y et al. (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. |
215. |
Lambert JC et al. (2001) Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. |
216. |
Chen G et al. (2001) A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. |
217. |
Chapman J et al. (2001) The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. |
218. |
Sass JO et al. (2001) Increased CSF cortisol in AD is a function of APOE genotype. |
219. |
Murray BJ et al. (2001) Effects of vagus nerve stimulation on respiration during sleep. |
220. |
Lesuisse C et al. (2001) Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. |
221. |
Goldstein FC et al. (2001) Apolipoprotein E and age at onset of Alzheimer's disease in African American patients. |
222. |
Bayer AU et al. (2002) Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. |
223. |
Cohen RM et al. (2001) Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women. |
224. |
Zareparsi S et al. (2002) Age at onset of Parkinson disease and apolipoprotein E genotypes. |
225. |
Mori E et al. (2002) Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. |
226. |
Liberman JN et al. (2002) Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. |
227. |
Dal Forno G et al. (2002) APOE genotype and survival in men and women with Alzheimer's disease. |
228. |
Crawford FC et al. (2002) APOE genotype influences acquisition and recall following traumatic brain injury. |
229. |
Scarmeas N et al. (2002) Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. |
230. |
Copin B et al. (2002) Apolipoprotein E-promoter single-nucleotide polymorphisms affect the phenotype of primary open-angle glaucoma and demonstrate interaction with the myocilin gene. |
231. |
Lambert JC et al. (2002) Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. |
232. |
Verpillat P et al. (2002) Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. |
233. |
Wilson RS et al. (2002) The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. |
234. |
Deary IJ et al. (2002) Cognitive change and the APOE epsilon 4 allele. |
235. |
Morrow JA et al. (2002) Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. |
236. |
Yamauchi T et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. |
237. |
Garcés C et al. (2002) Influence of birth weight on the apo E genetic determinants of plasma lipid levels in children. |
238. |
Enzinger C et al. (2003) Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. |
239. |
Bennett DA et al. (2003) Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. |
240. |
Schultz DW et al. (2003) Lack of an association of apolipoprotein E gene polymorphisms with familial age-related macular degeneration. |
242. |
Bunce C et al. (2003) Single-nucleotide polymorphisms and glaucoma severity. |
243. |
Matsumoto S et al. (2003) Modulation of the onset age in primary dystonia by APOE genotype. |
244. |
Pastor P et al. (2003) Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. |
245. |
Infante-Rivard C et al. (2003) Small babies receive the cardiovascular protective apolipoprotein epsilon 2 allele less frequently than expected. |
246. |
Harris FM et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. |
247. |
Qiu C et al. (2003) Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. |
248. |
Novaro GM et al. (2003) Association between apolipoprotein E alleles and calcific valvular heart disease. |
249. |
Long JR et al. (2003) APOE and TGF-beta1 genes are associated with obesity phenotypes. |
250. |
Ressiniotis T et al. (2004) The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma. |
251. |
Kantarci OH et al. (2004) Association of APOE polymorphisms with disease severity in MS is limited to women. |
252. |
Enzinger C et al. (2004) Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. |
253. |
De Stefano N et al. (2004) Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. |
254. |
Lund G et al. (2004) DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. |
255. |
Tiraboschi P et al. (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. |
256. |
Caselli RJ et al. (2004) Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. |
257. |
Li YJ et al. (2004) Apolipoprotein E controls the risk and age at onset of Parkinson disease. |
258. |
Prince JA et al. (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. |
259. |
Huang X et al. (2004) APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. |
260. |
Witsch-Baumgartner M et al. (2004) Maternal apo E genotype is a modifier of the Smith-Lemli-Opitz syndrome. |
261. |
Gottlieb DJ et al. (2004) APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. |
262. |
Koponen S et al. (2004) APOE-epsilon4 predicts dementia but not other psychiatric disorders after traumatic brain injury. |
263. |
Bray NJ et al. (2004) Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. |
264. |
Zwemmer J et al. (2004) Association of APOE polymorphisms with disease severity in MS is limited to women. |
265. |
Farlow MR et al. (2004) Impact of APOE in mild cognitive impairment. |
266. |
Ricci R et al. (2004) Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. |
267. |
Huang W et al. (2004) APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. |
268. |
Blair CK et al. (2005) APOE genotype and cognitive decline in a middle-aged cohort. |
269. |
Tsuang DW et al. (2005) Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. |
270. |
Steffens S et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. |
271. |
Dufouil C et al. (2005) APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. |
272. |
Devanand DP et al. (2005) Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. |
273. |
Malek G et al. (2005) Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. |
275. |
Faivre L et al. (2005) Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation. |
276. |
O'Hara R et al. (2005) Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. |
277. |
van den Elzen P et al. (2005) Apolipoprotein-mediated pathways of lipid antigen presentation. |
278. |
Gureje O et al. (2006) APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. |
279. |
Price DA et al. (2006) Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. |
280. |
Ye S et al. (2005) Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. |
281. |
Chang S et al. (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. |
282. |
Babiloni C et al. (2006) Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: a multicentric electroencephalogram study. |
283. |
Acciarri A et al. (2006) Apoe epsilon2-epsilon4 genotype is a possible risk factor for primary progressive aphasia. |
284. |
Baird PN et al. (2006) Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). |
285. |
Christensen K et al. (2006) The quest for genetic determinants of human longevity: challenges and insights. |
286. |
Peskind ER et al. (2006) Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. |
287. |
van der Flier WM et al. (2006) The effect of APOE genotype on clinical phenotype in Alzheimer disease. |
288. |
Wang JM et al. (2006) Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. |
289. |
Busch RM et al. (2007) ApoE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. |
290. |
Koutsis G et al. (2007) APOE epsilon4 is associated with impaired verbal learning in patients with MS. |
291. |
Borroni B et al. (2007) The effect of APOE genotype on clinical phenotype in Alzheimer disease. |
292. |
Zetterberg M et al. (2007) Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. |
293. |
Gozal D et al. (2007) APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. |
294. |
Lanterna LA et al. (2007) Meta-analysis of APOE genotype and subarachnoid hemorrhage: clinical outcome and delayed ischemia. |
295. |
Rovin BH et al. (2007) APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. |
296. |
Donnelly LA et al. (2008) Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. |
297. |
Allen NC et al. (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. |
298. |
Agosta F et al. (2009) Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. |
299. |
van Vliet P et al. (2009) APOE genotype modulates the effect of serum calcium levels on cognitive function in old age. |
300. |
Caselli RJ et al. (2009) Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. |
301. |
van der Walt A et al. (2009) Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. |
302. |
Ghaffar O et al. (2010) APOE epsilon4 and the cognitive genetics of multiple sclerosis. |
303. |
Bell RD et al. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. |
304. |
Dutta P et al. (2012) Myocardial infarction accelerates atherosclerosis. |
305. |
Silva F et al. (2013) High apolipoprotein E4 allele frequency in FXTAS patients. |
306. |
Rhinn H et al. (2013) Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease. |
307. |
Theendakara V et al. (2013) Neuroprotective Sirtuin ratio reversed by ApoE4. |